SCHEMBL8937368

SCHEMBL8937368

CCCOc1ccc(/C(=C/C(=O)N2CCN(C(=O)c3cc(OC)c(OC)c(OC)c3)CC2)c2ccccc2)cc1

nearest known ligand 0.60

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.60
CYP1A2 P05177 1/20 0.60
L3MBTL1 Q9Y468 1/20 0.56
HSD17B10 Q99714 2/20 0.53
TP53 P04637 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.52
HPGD P15428 1/20 0.50
DRD3 P35462 2/20 0.49
CDK5 Q00535 1/20 0.49
CDK5R1 Q15078 1/20 0.49
DRD2 P14416 1/20 0.48
KCNA5 P22460 1/20 0.48
NPC1 O15118 1/20 0.47
POLB P06746 1/20 0.47
SLC29A1 Q99808 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8937373 1.00 ALDH1A1 (0.60) ALDH1A1CYP1A2L3MBTL1HSD17B10TP53
SCHEMBL8937619 0.93 ALDH1A1 (0.58) ALDH1A1CYP1A2L3MBTL1HSD17B10TP53
SCHEMBL8937626 0.93 ALDH1A1 (0.58) ALDH1A1CYP1A2L3MBTL1HSD17B10TP53
SCHEMBL8937623 0.93 ALDH1A1 (0.58) ALDH1A1CYP1A2L3MBTL1HSD17B10TP53
SCHEMBL8937357 0.92 ALDH1A1 (0.52) ALDH1A1CYP1A2L3MBTL1HSD17B10TP53
SCHEMBL8937360 0.92 ALDH1A1 (0.52) ALDH1A1CYP1A2L3MBTL1HSD17B10TP53
SCHEMBL8937541 0.91 ALDH1A1 (0.59) ALDH1A1CYP1A2L3MBTL1HSD17B10TP53
SCHEMBL8937274 0.91 ALDH1A1 (0.55) ALDH1A1CYP1A2L3MBTL1HSD17B10TP53
SCHEMBL8937276 0.91 ALDH1A1 (0.55) ALDH1A1CYP1A2L3MBTL1HSD17B10TP53
SCHEMBL8937598 0.91 HPGD (0.60) ALDH1A1CYP1A2L3MBTL1HSD17B10TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5559109-A Method of treating a PAF-mediated pathology or for treating or preventing psoriasis, nephritis, asthma or shock by administering a PAF antagonist SANKKO COMPANY, LIMITED (JP) 1996-09-24 US disclosed
US-5556852-A PLATELET ACTIVATING FACTOR ANTAGONISTS SANKYO COMPANY, LIMITED (JP) 1996-09-17 US disclosed
EP-0395446-B1 N-acryloylpiperazine derivatives, their preparation and their use as paf antagonists SANKYO CO (JP) 1995-03-01 EP disclosed
US-5369106-A N-acryloylpiperazine derivatives, their preparation and their use of PAF antagonists SANKYO COMPANY, LIMITED (JP) 1994-11-29 US disclosed
US-5192766-A Platelet activating factor antagonist SANKYO COMPANY, LIMITED (JP) 1993-03-09 US disclosed
EP-0395446-A2 N-acryloylpiperazine derivatives, their preparation and their use as paf antagonists Sankyo Company Limited (JP) 1990-10-31 EP disclosed